TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07871435: GI-102 (CD80-IgG4 Fc-IL2v3) in Combination With Pasritamig in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) (JET-201)

Sponsor: GI Innovation, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 107 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT07871435 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07871435 Rescue Dossier →